Skip to main content

View full-text article in PMC

. 2012 May 11;153(7):3386–3393. doi: 10.1210/en.2011-1859

Table 1.

Pre-MCAO serum E2 and mortality at 24 h after MCAO

	Serum E2 (pg/ml)	Mortality (%)
Young adult intact	18.1 ± 3.2	0
Young adult OVX	6.3 ± 0.7^a,b	17^a,b
Young adult E2	25.8 ± 1.5	0
Aged intact	16.4 ± 3.0	40
Aged OVX	5.2 ± 0.2	33
Aged E2	36.6 ± 3.2^a,c	60^c

^a

P < 0.05 as compared with intact.

^b

P < 0.05 as compared with E2.

^c

P < 0.05 as compared with OVX.